A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate- Lowering Therapy.

Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate- Lowering Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Rilonacept (Primary)
  • Indications Gout
  • Focus Adverse reactions; Registrational
  • Acronyms RE-SURGE
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 24 Jul 2012 Additional lead trial investigator identified as reported by Clinical Trials Registry - India.
    • 09 Jun 2012 Results from a pooled analysis comparing outcomes in patients with and without tophi and/or polyarticular disease presented at the 13th Annual Congress of the European League Against Rheumatism.
    • 13 Dec 2011 NCT reports actual patient number is 1274.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top